{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:54Z","timestamp":1791559494895,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,20]]},"DOI":"10.7759\/cureus.114869","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:36:08Z","timestamp":1787243768000},"source":"Crossref","is-referenced-by-count":1,"title":["Encephalitis, High-Grade Atrioventricular Block, Acute Kidney Injury, and Hepatitis Following Atezolizumab Therapy: A Complex Case of Sequential Multiorgan Immune Checkpoint Inhibitor-Related Adverse Events"],"prefix":"10.7759","author":[{"given":"Umar","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bello Makama","family":"Tijjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmitha D","family":"Jagadeesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105490","article-title":"Immunomodulatory precision: a narrative review exploring the critical role of immune checkpoint inhibitors in cancer treatment","volume":"25","author":"Qiu J","year":"2024","unstructured":"Qiu J, Cheng Z, Jiang Z, Gan L, Zhang Z, Xie Z. Immunomodulatory precision: a narrative review exploring the critical role of immune checkpoint inhibitors in cancer treatment. Int J Mol Sci. 2024, 25:5490. 10.3390\/ijms25105490","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/aob-21-3","article-title":"A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy","volume":"7","author":"Peng S","year":"2022","unstructured":"Peng S, Bao Y . A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy. Ann Blood. 2022, 7:10.21037\/aob-21-3","journal-title":"Ann Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody development under treatment with immune-checkpoint inhibitors","volume":"7","author":"de Moel EC","year":"2019","unstructured":"de Moel EC, Rozeman EA, Kapiteijn EH, et al.. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol Res. 2019, 7:6-11. 10.1158\/2326-6066.CIR-18-0245","journal-title":"Cancer Immunol Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima TF","year":"2017","unstructured":"Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017, 22:470-479. 10.1634\/theoncologist.2016-0419","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-1238. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.52964\/AMJA.0647","article-title":"Problem-based review: immune-mediated complications of 'checkpoint inhibitors' for the acute physician","volume":"16","author":"Webb P","year":"2017","unstructured":"Webb P, Rice TW, Cooksley T. Problem-based review: immune-mediated complications of 'checkpoint inhibitors' for the acute physician. Acute Med. 2017, 16:21-24.","journal-title":"Acute Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni A","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022, 13:779691. 10.3389\/fimmu.2022.779691","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi G","year":"2023","unstructured":"Emmi G, Bettiol A, Gelain E, et al.. Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023, 19:378-393. 10.1038\/s41584-023-00958-w","journal-title":"Nat Rev Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0861","article-title":"Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data","volume":"17","author":"Shimozaki K","year":"2021","unstructured":"Shimozaki K, Sukawa Y, Sato Y, et al.. Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. Future Oncol. 2021, 17:2593-2603. 10.2217\/fon-2020-0861","journal-title":"Future Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100611","article-title":"The timing, trajectory, and incidence of immune-related adverse events in NSCLC treated with atezolizumab","volume":"4","author":"Smith KE","year":"2023","unstructured":"Smith KE, Pritzl SL, Yu W, et al.. The timing, trajectory, and incidence of immune-related adverse events in NSCLC treated with atezolizumab. JTO Clin Res Rep. 2023, 4:100611. 10.1016\/j.jtocrr.2023.100611","journal-title":"JTO Clin Res Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071677","article-title":"Glial cell expression of PD-L1","volume":"20","author":"Chauhan P","year":"2019","unstructured":"Chauhan P, Lokensgard JR. Glial cell expression of PD-L1. Int J Mol Sci. 2019, 20:1677. 10.3390\/ijms20071677","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.759972","article-title":"Myocardial PD-L1 expression in patients with ischemic and non-ischemic heart failure","volume":"8","author":"Kushnareva E","year":"2021","unstructured":"Kushnareva E, Kushnarev V, Artemyeva A, Mitrofanova L, Moiseeva O. Myocardial PD-L1 expression in patients with ischemic and non-ischemic heart failure. Front Cardiovasc Med. 2021, 8:759972. 10.3389\/fcvm.2021.759972","journal-title":"Front Cardiovasc Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i28.3322","article-title":"Immunostaining of PD-1\/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma","volume":"17","author":"Wang BJ","year":"2011","unstructured":"Wang BJ, Bao JJ, Wang JZ, et al.. Immunostaining of PD-1\/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 2011, 17:3322-3329. 10.3748\/wjg.v17.i28.3322","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100252","article-title":"Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States","volume":"6","author":"Jain P","year":"2021","unstructured":"Jain P, Bugarin JG, Guha A, et al.. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open. 2021, 6:100252. 10.1016\/j.esmoop.2021.100252","journal-title":"ESMO Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen CN","year":"2021","unstructured":"Owen CN, Bai X, Quah T, et al.. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol. 2021, 32:917-925. 10.1016\/j.annonc.2021.03.204","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini A","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, Vogrig A. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021, 96:754-766. 10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104595","article-title":"Central nervous system complications of immune checkpoint inhibitors: a comprehensive review","volume":"206","author":"Lopes S","year":"2025","unstructured":"Lopes S, Pabst L, Bahougne T, et al.. Central nervous system complications of immune checkpoint inhibitors: a comprehensive review. Crit Rev Oncol Hematol. 2025, 206:104595. 10.1016\/j.critrevonc.2024.104595","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012122","article-title":"Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review","volume":"97","author":"Nersesjan V","year":"2021","unstructured":"Nersesjan V, McWilliam O, Krarup LH, Kondziella D. Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review. Neurology. 2021, 97:e191-e202. 10.1212\/WNL.0000000000012122","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco R","year":"2021","unstructured":"Velasco R, Villagr\u00e1n M, Jov\u00e9 M, et al.. Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol. 2021, 78:864-873. 10.1001\/jamaneurol.2021.0249","journal-title":"JAMA Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-022-00147-w","article-title":"The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: including myocarditis and the new entity of non-inflammatory left ventricular dysfunction","volume":"8","author":"Andres MS","year":"2022","unstructured":"Andres MS, Ramalingam S, Rosen SD, et al.. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: including myocarditis and the new entity of non-inflammatory left ventricular dysfunction. Cardiooncology. 2022, 8:21. 10.1186\/s40959-022-00147-w","journal-title":"Cardiooncology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer\u00a0\u2014\u00a0a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Tocchetti CG","year":"2024","unstructured":"Tocchetti CG, Farmakis D, Koop Y, et al.. Cardiovascular toxicities of immune therapies for cancer\u00a0\u2014\u00a0a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2024, 26:2055-2076. 10.1002\/ejhf.3340","journal-title":"Eur J Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-245. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref23","unstructured":"WHO-UMC causality assessment system. (2025). https.\/\/alvigilance.siralance.com\/who-umc-causality-assessment-system\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/420372-encephalitis-high-grade-atrioventricular-block-acute-kidney-injury-and-hepatitis-following-atezolizumab-therapy-a-complex-case-of-sequential-multiorgan-immune-checkpoint-inhibitor-related-adverse-events","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:36:14Z","timestamp":1787243774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/420372-encephalitis-high-grade-atrioventricular-block-acute-kidney-injury-and-hepatitis-following-atezolizumab-therapy-a-complex-case-of-sequential-multiorgan-immune-checkpoint-inhibitor-related-adverse-events"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.114869","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}